Bio (BIO) Share Value Rose While Fort Washington Investment Advisors INC Has Decreased Its Position

Bio-Rad Laboratories, Inc. (NYSE:BIO) LogoInvestors sentiment increased to 1.46 in Q1 2019. Its up 0.45, from 1.01 in 2018Q4. It is positive, as 29 investors sold BIO shares while 82 reduced holdings. 61 funds opened positions while 101 raised stakes. 17.40 million shares or 11.49% less from 19.66 million shares in 2018Q4 were reported. Barclays Public has 0% invested in Bio-Rad Laboratories, Inc. (NYSE:BIO). Hsbc Hldgs Public Ltd Co owns 19,472 shares or 0.01% of their US portfolio. Leuthold holds 1,749 shares or 0.07% of its portfolio. Financial Counselors has invested 0.02% in Bio-Rad Laboratories, Inc. (NYSE:BIO). 7,036 were accumulated by Schroder Mngmt Grp Inc. Neuberger Berman Grp Inc Lc holds 114,711 shares. Merian Global Invsts (Uk) Ltd has invested 0.07% in Bio-Rad Laboratories, Inc. (NYSE:BIO). 6,465 were accumulated by Bluecrest Cap Management Limited. Co Fincl Bank, a Missouri-based fund reported 815 shares. Ontario Teachers Pension Plan Board holds 1,125 shares. Gabelli Funds holds 0.07% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 38,600 shares. Dynamic Management holds 2.02% in Bio-Rad Laboratories, Inc. (NYSE:BIO) or 1,827 shares. Mariner Limited Liability owns 820 shares. Martingale Asset Mgmt L P, a Massachusetts-based fund reported 1,289 shares. Aqr Capital Lc invested in 247,192 shares or 0.08% of the stock.

Fort Washington Investment Advisors Inc decreased its stake in Bio (BIO) by 12.73% based on its latest 2019Q1 regulatory filing with the SEC. Fort Washington Investment Advisors Inc sold 25,544 shares as the company’s stock rose 6.00% . The hedge fund held 175,158 shares of the capital goods company at the end of 2019Q1, valued at $53.54 million, down from 200,702 at the end of the previous reported quarter. Fort Washington Investment Advisors Inc who had been investing in Bio for a number of months, seems to be less bullish one the $9.51B market cap company. The stock increased 1.04% or $3.3 during the last trading session, reaching $319.13. About 170,094 shares traded. Bio-Rad Laboratories, Inc. (NYSE:BIO) has risen 3.54% since August 15, 2018 and is uptrending. It has outperformed by 3.54% the S&P500.

Fort Washington Investment Advisors Inc, which manages about $44.90 billion and $8.90 billion US Long portfolio, upped its stake in Brunswick Corp Common (NYSE:BC) by 202,000 shares to 282,000 shares, valued at $14.19M in 2019Q1, according to the filing. It also increased its holding in Vanguard Index Fds Sandp 500 Etf Shs (VOO) by 54,954 shares in the quarter, for a total of 117,702 shares, and has risen its stake in Movado Group Inc Common (NYSE:MOV).

More notable recent Bio-Rad Laboratories, Inc. (NYSE:BIO) news were published by: Benzinga.com which released: “The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings – Benzinga” on August 01, 2019, also Seekingalpha.com with their article: “Bio-Rad finance chief to retire – Seeking Alpha” published on January 03, 2019, Finance.Yahoo.com published: “Moody’s Upgrades Bio-Rad to Baa2, Reflecting Recent Improvement in the Company’s Operating Performance – Yahoo Finance” on June 27, 2019. More interesting news about Bio-Rad Laboratories, Inc. (NYSE:BIO) were released by: Benzinga.com and their article: “Earnings Scheduled For May 8, 2019 – Benzinga” published on May 08, 2019 as well as Finance.Yahoo.com‘s news article titled: “Bio-Rad Reports Second-Quarter 2019 Financial Results – Yahoo Finance” with publication date: August 01, 2019.

Bio-Rad Laboratories, Inc. (NYSE:BIO) Ratings Coverage

Among 2 analysts covering Bio-Rad Laboratories (NYSE:BIO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Bio-Rad Laboratories has $350 highest and $34000 lowest target. $343.33’s average target is 7.58% above currents $319.13 stock price. Bio-Rad Laboratories had 6 analyst reports since February 23, 2019 according to SRatingsIntel. On Friday, March 1 the stock rating was maintained by Deutsche Bank with “Buy”. Barclays Capital maintained the shares of BIO in report on Friday, March 1 with “Buy” rating.

Bio-Rad Laboratories, Inc. (NYSE:BIO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.